Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
EXPERT CONSENSUS

Coronavirus disease vaccination in heart failure: No time to waste

Vaccination contre le coronavirus dans l’insuffisance cardiaque : pas de temps à perdre

Jerome Roncalli\textsuperscript{a,b}, François Roubille\textsuperscript{c,*}, Nicolas Lamblin\textsuperscript{d}, Nicolas Girerd\textsuperscript{e}, Frédéric Mouquet\textsuperscript{f}, Nicolas Chapet\textsuperscript{g}, Camille Roubille\textsuperscript{h}, Emmanuelle Berthelot\textsuperscript{i}, Katie Galois\textsuperscript{j}, Pascal Battistella\textsuperscript{k}, Guillaume Jondeau\textsuperscript{l}, Jean-Michel Tartiere\textsuperscript{m}, Sylvain Aguilhon\textsuperscript{k}, Jean-Pierre Gueffet\textsuperscript{n}, Muriel Salvat\textsuperscript{o}, Thibaud Damy\textsuperscript{p}, Michel Galinier\textsuperscript{a,q}, for the Heart Failure Group of the French Society of Cardiology

\textsuperscript{a} Fédération des services de cardiologie, faculté de médecine, Institute CARDIOMET, Université Paul Sabatier-Toulouse III, CHU de Toulouse-Rangueil, 31059 Toulouse, France
\textsuperscript{b} CIC-Biotherapy 1436, Team 6–I2MC, 31432 Toulouse, France
\textsuperscript{c} Inserm, CNRS, PhyMedExp, Department of Cardiology, CHU de Montpellier, université de Montpellier, 34295 Montpellier, France
\textsuperscript{d} Department of Cardiology, Université de Lille, 59000 Lille, France
\textsuperscript{e} Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists), F-CRIN Network, centre d’investigations cliniques 1433, université de Lorraine, CHRU de Nancy, 54000 Nancy, France
\textsuperscript{f} Soins intensifs cardiologiques, hôpital privé Le Bois, 59000 Lille, France
\textsuperscript{g} Department of Clinical Pharmacy, CHU de Montpellier, 34295 Montpellier, France
\textsuperscript{h} Inserm U1046, CNRS UMR 9214, PhyMedExp, Department of Internal Medicine, CHU de Montpellier, University of Montpellier, 34295 Montpellier, France
\textsuperscript{i} Department of Cardiology, Hôpital Bicêtre, AP–HP, 94270 Le-Kremlin-Bicêtre, France

Available online 24 May 2021

Abbreviations: CHF, Chronic Heart Failure; COVID-19, Coronavirus Disease 2019; HF, Heart Failure; mRNA, messenger Ribonucleic Acid; RNA, Ribonucleic Acid; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.

* Corresponding author.

E-mail address: francois.roubille@gmail.com (F. Roubille).

https://doi.org/10.1016/j.acvd.2021.04.004

1875-2136/© 2021 Elsevier Masson SAS. All rights reserved.
Background

Viral diseases are well-established factors responsible for acute decompensation in chronic heart failure (CHF) (Fig. 1). The underlying pathophysiology includes increased myocardial work and an infection-related inflammatory response, which further contribute to the increase in diastolic and/or systolic dysfunction. Direct myocardial viral involvement may also lead to myocarditis, which can worsen pre-existing ventricular dysfunction. Thus, viruses are expected to increase cardiovascular mortality in heart failure (HF), and influenza vaccination might be considered as an effective treatment strategy to improve survival in HF [1].

Impact of coronavirus disease 2019 on cardiovascular disease

In the context of the coronavirus disease 2019 (COVID-19) pandemic, the risk of cardiac complications (including worsening CHF) reported in the international CAPACITY-COVID registry appeared to be relatively low, with the notable exception of pulmonary embolisms, even in patients with a history of cardiovascular disease [2]. Indeed, in 3011 patients hospitalized for pulmonary involvement related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (mean age, 67 years; 31% with cardiovascular history), cardiac complications occurred in 11.6% of patients, with atrial fibrillation (4.7%) being the most common, followed by HF (1.8%), acute coronary syndrome (0.5%) and ventricular arrhythmia (0.5%). Myocarditis occurred in only 0.1% of patients, whereas pulmonary embolism was diagnosed in 6.6% [2]. COVID-19-related myocarditis...
is currently under investigation in the large multicentre MYOCOVID French registry (ClinicalTrials.gov identifier: NCT04375748).

Regarding the impact of COVID-19 on patient outcomes, an observational single-centre study [3], including 283 patients referred, on the basis of typical symptoms of acute HF (raised B-type natriuretic protein and echocardiogram), to a district hospital in Bristol (England, UK) over two 8-week periods preceding and following the first reported case of COVID-19-related death, showed a sizeable, albeit not statistically significant, drop of 27% in the number of patients seen between the two periods (164 vs. 119 patients). In the absence of vaccination, this decrease was most likely related to the fear of social contact during the lockdown, and the subsequent reluctance of patients to go to the hospital and/or of primary care physicians to refer their patients during this period. However, the 30-day mortality rate was twice as high in the period following the first COVID-19-related death (21% vs. 11%), which represents an increase of 90% in the relative risk. A sensitivity analysis indicated that the increase in mortality was driven by COVID-19 positive status, which reinforces the expected beneficial role of vaccination in patients with HF.

Impact of cardiovascular disease on COVID-19-related outcome

Patients with CHF are often elderly, and usually present with several co-morbidities, including hypertension, obesity, type 2 diabetes, coronary artery disease, renal failure and chronic obstructive pulmonary disease, so they are likely to be infected with SARS-CoV-2 and also to develop severe forms of COVID-19 pneumonia. Indeed, the underlying heart disease is expected to worsen the consequences of lung infection [4,5]. Thus, patients with pre-existing cardiovascular diseases have paid a significant price during this pandemic, as was immediately highlighted by the first data from China, showing that approximately 50% of patients hospitalized for a COVID-19 infection had a history of chronic disease, which corresponded to a cardiovascular history in 80% of cases. Whereas COVID-19-associated mortality was initially reported to be 2.3%, it was soon described as being much higher in people with diabetes (7.3%) and in patients with pre-existing cardiovascular disease (10.5%). A meta-analysis of six studies, including 1527 subjects with COVID-19 in China, confirmed that cardiovascular history and metabolic co-morbidities increased the risk of severe forms of COVID-19. Patients with a cardiovascular history had a 3-fold increase in the risk of intensive care hospitalization, and a 2-fold increase was reported in patients with hypertension or diabetes [6]. These results were confirmed by Italian data from 1591 patients admitted to intensive care units for COVID-19 infection, with 68% of these severe patients presenting with hypertension [7].

The special relationship between HF and COVID-19

Patients with HF are paying a heavy price to the COVID-19 pandemic by developing severe and potentially fatal pulmonary diseases, whereas congestive flare-ups occurring in the course of the viral attack are uncommon [2,8]. The deleterious impact of CHF on the prognosis of patients hospitalized for COVID-19 was confirmed by data from the Mount Sinai Healthcare System Hospitals (New York, USA). In 6439 patients admitted for COVID-19 (mean age, 64 years), a history of CHF was associated with a 3.6-fold increase in the risk of requiring assisted ventilation, and a 1.9-fold increase in the risk of death, regardless of left ventricular ejection fraction [9]. Another recent study suggested that a decreased left ventricular ejection fraction (< 55%) was associated with an even poorer prognosis [10]. In a large database in North Carolina, USA, the rate of in-hospital mortality of patients with HF hospitalized with COVID-19 was 24.2%, compared with 2.6% and 4.6% in patients hospitalized during the same time frame for acute HF or other reasons, respectively [11]. Of particular concern, patients with a history of CHF are prone to HF worsening while being affected by COVID-19 [12], which further increases the risk of adverse events within the course of the disease.

The mechanisms underlying the susceptibility of patients with HF to develop severe forms of COVID-19 infection remain a matter of debate [13]. Direct myocardial damage caused by the virus binding to a membrane protein is suspected. However, indirect mechanisms are likely to predominate, in relation to hypoxaemia induced by pulmonary involvement, catecholaminergic flooding, microthrombi and, above all, an excessive immune response causing intense inflammation, with a significant release of cytokines (interleukin-6 and interleukin-17), which may, in turn, have a toxic myocardial effect. Moreover, there is no evidence regarding any difference between HF with reduced and preserved ejection fraction.

The vital importance of SARS-CoV-2 vaccination in patients with HF

For all the aforementioned reasons, our expert panel from the Heart Failure Group of the French Society of Cardiology strongly advocates for vaccination against COVID-19 to be offered to patients with CHF as soon as possible, as they represent a particularly vulnerable population (central illustration). HF is a clear established risk factor for poor outcomes, and patients who are decompensated and/or those with poor functional status should be considered at the highest risk of COVID-19 infection, and thus have to be considered for benefit from COVID-19 vaccination [14].

More than four types of COVID-19 vaccines are currently or soon will be available worldwide, which include nucleic acid-based vaccines using genetic material (either ribonucleic acid [RNA] or deoxyribonucleic acid [DNA]), protein subunit vaccines containing specific isolated and harmless SARS-CoV-2-derived proteins, viral vector vaccines containing a weakened version of a live virus and live-virus vaccines, usually corresponding to a weakened version of the virus [15]. Nucleic acid-based vaccines contain no recognizable virus, but only its genetic material, which then migrates into human cells to make them synthesize the virus’s identity card. The first available RNA vaccines need to be stored at ultra-cold temperatures (−70 °C or below), which requires
specialized cold storage equipment, but the other RNA-based vaccines to come will only have to be stored at low temperatures, which will simplify the process. All types of COVID-19 vaccines are expected to be as safe for patients with CHF as for people without CHF, and no alert related to COVID vaccination in these patients has been reported so far. Although there has been no warning signal about possible adverse events of vaccination in patients with HF, no published data are yet available on COVID-19 vaccination in this population. However, influenza and pneumococcus vaccinations are recommended in these patients, without any tolerance issues, which also suggests a benefit in this population.

Results from monitoring efforts after COVID-19 vaccination are reassuring. Fortunately, some people have no side effects after COVID-19 vaccination. Others have reported common side effects after COVID-19 vaccination, such as swelling, redness and pain at the injection site, fever, headache, tiredness, muscle pain, chills and nausea. These reactions are common and transient, resolving within a couple of days after onset. A small number of people have had an anaphylaxis reaction after vaccination, but this is extremely rare; this is why, after receiving a COVID-19 vaccine, you are asked to stay for 15–30 minutes for observation, in case you have a severe allergic reaction and need treatment. Overall, more than 145 million doses of COVID-19 vaccines were administered in the USA from 14 December 2020 to 29 March 2021. During this time, the Vaccine Adverse Event Reporting System (VAERS) received 2509 reports of death (0.0017%) among people who received a COVID-19 vaccine. A review by Centers for Disease Control and Prevention and Food and Drug Administration physicians of available clinical information, including death certificates and autopsy and medical records, revealed no evidence that vaccination contributed to patient deaths [16].

The incidence of serious adverse events was similar in the messenger RNA (mRNA) COVID-19 vaccines and placebo groups, without evidence of cardiovascular complications [17,18]. However, although more data are needed to understand the extent and mechanism of hypertension after mRNA-based vaccination, a few data indicate that in elderly patients with a history of hypertension and/or significant previous cardiovascular co-morbidities, control of blood pressure before vaccination and monitoring after vaccination, including symptom screening, may be warranted [19]. Moreover, based on the review of clinical and non-clinical data, there is currently no evidence to suggest an association between thrombotic events and the use of the AstraZeneca COVID-19 vaccine [20]. Finally, data from Israel’s largest health care organization, a study performed in a nationwide mass vaccination setting, suggest that the mRNA vaccine is effective for a wide range of COVID-19-related outcomes, a finding that is consistent with that of a randomized trial without evidence of any adverse events related to the vaccination [21].

Conclusions

In conclusion, the prognosis of patients with CHF is greatly jeopardized in case of SARS-CoV-2 infection, as a result of the poor outcomes associated with co-morbidities, which largely supports the prioritization of vaccination against COVID-19. Our group of experts therefore does believe that patients with HF should receive vaccination as soon as possible, and that there is no time to waste!

Funding

None.

Disclosure of interest

The authors declare that they have no competing interest.

References

[1] Modin D, Jorgensen ME, Gislason G, et al. Influenza vaccine in heart failure. Circulation 2019;139:575–86.
[2] Linschoten M, Peters S, van Smeden M, et al. Cardiac complications in patients hospitalised with COVID-19. Eur Heart J Acute Cardiovasc Care 2020;9:817–23.
[3] Doolub G, Wong C, Hewitson L, et al. Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre experience from the south-west of the UK. ESC Heart Fail 2021;8:1691–5.
[4] Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259–60.
[5] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[6] Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531–8.
[7] Grasselli G, Zangrillo A, Zanello A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–81.
[8] European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. (Last update: 10 June 2020). Available at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
[9] Alvarez-Garcia J, Lee S, Gupta A, et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol 2020;76:2334–48.
[10] Soulat-Dufour L, Lang S, Ederhy S, et al. Left ventricular ejection fraction: an additional risk marker in COVID-19. Arch Cardiovasc Dis 2020;113:760–2.
[11] Bhatt AS, Jering KS, Vaduganathan M, et al. Clinical outcomes in patients with heart failure hospitalized with COVID-19. JACC Heart Fail 2021;9:65–73.
[12] Rey JR, Caro-Codon J, Rosillo SO, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail 2020;22:2205–15.
[13] Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation 2020;141:1648–55.
[14] Driggin E, Maddox TM, Ferdinand KC, et al. ACC health policy statement on cardiovascular disease considerations for COVID-19 vaccine prioritization: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:1938–48.
[15] Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 vaccine development: current status. Mayo Clin Proc 2020;95:2172–88.
[16] Centers for Disease Control Prevention. Ensuring COVID-19 vaccine safety in the US; 2021 [Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html].

[17] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.

[18] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–15.

[19] Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension 2021;77:e56–7.

[20] European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 vaccine (ChAdOx1-S [recombinant])—COVID-19 Vaccine AstraZeneca (Other viral vaccines); 2021 [Available at: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf].

[21] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–23.